Usefulness of Inflammatory Markers for the Prediction of Postherpetic Neuralgia in Patients with Acute Herpes Zoster.
- Author:
Jun Young KIM
1
;
Gyeong Hun PARK
;
Min Ji KIM
;
Hyun Bo SIM
;
Weon Ju LEE
;
Seok Jong LEE
;
Shin Woo KIM
;
Young Hoon JEON
;
Yong Hyun JANG
;
Do Won KIM
Author Information
- Publication Type:Original Article
- Keywords: Herpes zoster; Inflammation; Postherpetic neuralgia
- MeSH: Blood Cell Count; Blood Sedimentation; C-Reactive Protein; Diagnosis; Herpes Zoster*; Herpesvirus 3, Human; Humans; Inflammation; Lymphocyte Count; Multivariate Analysis; Neuralgia, Postherpetic*; Neurons
- From:Annals of Dermatology 2018;30(2):158-163
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Increasing evidence suggests a pivotal role for neuronal inflammation in response to replicating varicella zoster virus in the development of postherpetic neuralgia (PHN). OBJECTIVE: In this study, we investigated the value of serum levels of various inflammatory markers in acute herpes zoster (HZ) as predictors for the development of PHN. METHODS: A total of 116 patients with acute HZ were enrolled in this study. We measured scores on the pain visual analogue scale (VAS) at baseline and at 1, 3, and 6 months after diagnosis of HZ. We defined PHN as pain greater than 1 on the VAS lasting for more than 6 months. Serum samples for laboratory assay, including complete blood count were obtained at the initial visit. Correlations between the levels of each inflammatory marker and the development of PHN were evaluated. RESULTS: Levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), lymphocyte count, and albumin showed significant correlations with development of PHN in univariate analysis. Levels of ESR, CRP, and lymphocyte count also showed significant correlations in multivariate analysis. ESR level showed stronger correlations with development of PHN than levels of CRP and lymphocyte count. CONCLUSION: In this study, we confirmed that elevated ESR was an independent and significant predictor of PHN in patients with acute HZ. To validate these results, further well-designed, randomized clinical trials are needed.
